-
Burosumab, sold
under the
brand name Crysvita, is a
human monoclonal antibody medication approved 2018 for the
treatment of X-linked hypophosphatemia...
- Children’s
Hospital Los Angeles. 2015-11-11.
Retrieved 2022-12-27. "
Burosumab treatment in
adults with X-linked hypophosphataemia: 96-w**** patient-reported...
- Kirin,
Mereo Biopharma and
Daiichi Sankyo.
Ultragenyx has
three products Burosumab,
Triheptanoin and
Vestronidase alfa that have
received FDA
approval and...
- for this condition,
called burosumab. It was then
licensed by the US Food and Drug
Administration in June 2018
Burosumab is
shown to
target the major...
-
hypophosphataemia treated with a
human monoclonal antibody against FGF23
called burosumab improved significantly compared to
conventional therapy.
Online Mendelian...
-
Aluminium chlorohydrate M05BX03
Strontium ranelate M05BX04
Denosumab M05BX05
Burosumab M05BX06
Romosozumab M05BX07
Vosoritide M05BX08
Menatetrenone M05BX53 Strontium...
- (bFGF), 4, 8, 9, 18, 23)
Selpercatinib Sprifermin Trafermin Antibodies:
Burosumab (against FGF23) FGFR4 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,...
- (bFGF), 4, 8, 9, 18, 23)
Selpercatinib Sprifermin Trafermin Antibodies:
Burosumab (against FGF23) FGFR4 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,...
- (bFGF), 4, 8, 9, 18, 23)
Selpercatinib Sprifermin Trafermin Antibodies:
Burosumab (against FGF23) FGFR4 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,...
- (bFGF), 4, 8, 9, 18, 23)
Selpercatinib Sprifermin Trafermin Antibodies:
Burosumab (against FGF23) FGFR4 Agonists:
Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,...
